Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Last trade$0.4234
Day change+$0.0171 (+4.21%)
Day range$0.375 – $0.449
Volume266,412
Market cap$6M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$5.82M
Price / earnings
—
Price / book
0.17×
Price / sales
1,743.59×
EV / sales
-9,597.84×
EV / EBITDA
2.1×
Profitability
Earnings per share
-$1.00
Return on assets
-36.44%
Return on equity
-41.47%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
9.67×
Quick ratio
9.67×
Cash ratio
9.52×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.74M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for APRE, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$3.34K
$1.85K
$118.11K
$162.46K
$205.82K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$3.34K
$1.85K
$118.11K
$162.46K
$205.82K
Selling, general and administrative
$1.83M
$1.57M
$1.82M
$1.64M
$1.48M
$1.59M
$1.76M
$1.07M
Research and development
$3.34M
$2.46M
$1.61M
$1.01M
$1.64M
$1.91M
$2.48M
$2.36M
Total operating expenses
$5.17M
$4.03M
$3.43M
$2.65M
$3.12M
$3.51M
$4.25M
$3.43M
Operating income
-$5.17M
-$4.03M
-$3.43M
-$2.64M
-$3.12M
-$3.39M
-$4.09M
-$3.23M
Interest expense
$360.7K
$358.92K
$134.78K
$0
$150.67K
$178.03K
$204.73K
$0
Income before taxes
-$4.81M
-$3.59M
-$3.29M
-$2.46M
-$2.97M
-$3.24M
-$3.93M
-$2.89M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$4.81M
-$3.59M
-$3.29M
-$2.46M
-$2.97M
-$3.24M
-$3.93M
-$2.89M
Net income attributable to common shareholders
-$4.81M
-$3.59M
-$3.29M
-$2.46M
-$2.97M
-$3.24M
-$3.93M
-$2.89M
EBITDA
-$5.17M
-$4.03M
-$3.42M
-$2.64M
-$3.11M
-$3.38M
-$4.08M
-$3.22M
Basic earnings per share
-$0.09
-$0.07
-$0.22
-$0.32
-$0.47
-$0.53
-$0.66
-$0.49
Diluted earnings per share
-$0.09
-$0.07
-$0.22
-$0.32
-$0.47
-$0.53
-$0.66
-$0.49
Recent news
Company coverage with links to the original publishers.
Aprea Therapeutics, a clinical-stage precision medicine oncology company, announced that its President and CEO Oren Gilad will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026. The company is developing targeted cancer therapies including APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both in clinical development for solid tumors.
Aprea Therapeutics reported positive preclinical and early-stage clinical data for its next-generation WEE1 inhibitor, APR-1051, in treating HPV-positive head and neck squamous cell carcinoma. The drug showed potent single-agent activity and enhanced synergy with anti-PD-1 therapies in preclinical models, and demonstrated early disease control in a Phase 1 trial.
Aprea Therapeutics reported progress in its clinical trials for ATRN-119 and APR-1051, with early evidence of anti-tumor activity and continued enrollment. The company has sufficient cash runway into early Q2 2026.
Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape